{"schema_version":"1","generated_at":"2026-10-29T13:58:32.119Z","data_as_of":null,"url":"https://www.findmykol.com/kol/elizabeth-tan-chiu","json_url":"https://www.findmykol.com/kol/elizabeth-tan-chiu/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"elizabeth-tan-chiu","name":"Elizabeth Tan-Chiu","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"city":"Tampa","state":"FL","region":{"label":"Southeast","url":"https://www.findmykol.com/region/southeast"}},"identifiers":{"npi":"1538113931","openalex":"A5035165318"},"summary":"Elizabeth Tan-Chiu is an Oncology physician. OpenAlex indexes 80 publications with 18,474 citations (h-index 26); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the FindMyKOL directory.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":80,"cited_by_count":18474,"h_index":26,"latest_activity_year":2025,"citation_standing":{"top_percent":10,"cohort":"Hematology / Oncology","method":"https://www.findmykol.com/about#citation-standing"},"source":"works"},"trials":{"count":1,"shown":0,"withheld":0,"rows":[],"source":"trials"},"payments":{"company_count":8,"program_years":{"first":2021,"last":null},"rows_total":8,"shown":3,"withheld":5,"rows":[{"payer":"Eli Lilly and Company","program_year":2025,"amount_usd":1250,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1538113931"},{"payer":"Lilly USA, LLC","program_year":2025,"amount_usd":121,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1538113931"},{"payer":"PFIZER INC.","program_year":2025,"amount_usd":63.49,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1538113931"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1538113931","source":"payments"},"prescribing":{"data_year":2024,"areas_total":2,"areas_shown":2,"areas":[{"area":"Nervous system","share_pct":57.1,"classes_total":1,"classes":[{"class":"Phenothiazine","setting":"prescribed","share_pct":57.1,"drugs":[{"name":"Prochlorperazine Maleate","share_pct":100}],"max_beneficiaries":null}]},{"area":"Cancer & immunology","share_pct":42.9,"classes_total":1,"classes":[{"class":"Aromatase Inhibitor","setting":"prescribed","share_pct":42.9,"drugs":[{"name":"Anastrozole","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2024,"office_pct":0,"facility_pct":100},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor–Positive/HER2-Negative Advanced or Metastatic Breast Cancer","year":2021,"journal":"Clinical Cancer Research","source_url":"https://doi.org/10.1158/1078-0432.ccr-20-4131","status":"verified"},{"title":"Abstract PD1-09: Phase 2 safety and efficacy results of TAK-228 in combination with exemestane or fulvestrant in postmenopausal women with ER-positive/HER2-negative metastatic breast cancer previously treated with everolimus","year":2019,"journal":"Cancer Research","source_url":"https://doi.org/10.1158/1538-7445.sabcs18-pd1-09","status":"verified"},{"title":"PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study","year":2018,"journal":"British Journal of Cancer","source_url":"https://doi.org/10.1038/s41416-018-0340-2","status":"verified"},{"title":"Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","year":2017,"journal":"The Lancet Oncology","source_url":"https://doi.org/10.1016/s1470-2045(17)30717-9","status":"verified"},{"title":"A randomized, double-blind study of PF-05280014 (a potential trastuzumab biosimilar) vs trastuzumab, both in combination with paclitaxel, as first-line treatment for HER2-positive metastatic breast cancer","year":2017,"journal":"Annals of Oncology","source_url":"https://doi.org/10.1093/annonc/mdx365.001a","status":"verified"}],"source":"works"},"contact":{"address_1":"12902 USF MAGNOLIA DR","city":"Tampa","state":"FL","zip":"336129416","phone":"866-837-4112","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1538113931","source":"identity"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":5,"publications":45}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2025-06-18","provider_certified":"2025-06-18","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}